With Bayer AG already lending a helping hand, CureVac NV has enlisted another pharma giant in Novartis AG to assist with the production of its investigational mRNA COVID-19 vaccine.
The Swiss major has agreed to manufacture the mRNA and bulk drug product for CureVac's vaccine candidate CVnCoV, noting that "preparations for the start of production, technology transfer and test runs are already underway
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?